- Home
- TLSA vs IPSC Comparison
TLSA vs IPSC Comparison
Compare TLSA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- IPSC
- Stock Information
- Founded
- TLSA 2013
- IPSC 2019
- Country
- TLSA United Kingdom
- IPSC United States
- Employees
- TLSA N/A
- IPSC N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- TLSA Health Care
- IPSC Health Care
- Exchange
- TLSA Nasdaq
- IPSC Nasdaq
- Market Cap
- TLSA 87.8M
- IPSC 88.4M
- IPO Year
- TLSA 2000
- IPSC 2021
- Fundamental
- Price
- TLSA $0.74
- IPSC $0.91
- Analyst Decision
- TLSA
- IPSC Strong Buy
- Analyst Count
- TLSA 0
- IPSC 4
- Target Price
- TLSA N/A
- IPSC $11.00
- AVG Volume (30 Days)
- TLSA 442.0K
- IPSC 562.3K
- Earning Date
- TLSA 01-28-2025
- IPSC 03-13-2025
- Dividend Yield
- TLSA N/A
- IPSC N/A
- EPS Growth
- TLSA N/A
- IPSC N/A
- EPS
- TLSA N/A
- IPSC N/A
- Revenue
- TLSA N/A
- IPSC $2,684,000.00
- Revenue This Year
- TLSA N/A
- IPSC $230.56
- Revenue Next Year
- TLSA N/A
- IPSC $31.85
- P/E Ratio
- TLSA N/A
- IPSC N/A
- Revenue Growth
- TLSA N/A
- IPSC 7.88
- 52 Week Low
- TLSA $0.41
- IPSC $0.87
- 52 Week High
- TLSA $1.74
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- TLSA 44.91
- IPSC 33.31
- Support Level
- TLSA $0.68
- IPSC $0.87
- Resistance Level
- TLSA $0.80
- IPSC $1.19
- Average True Range (ATR)
- TLSA 0.08
- IPSC 0.09
- MACD
- TLSA 0.01
- IPSC -0.00
- Stochastic Oscillator
- TLSA 34.34
- IPSC 12.75
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.